Chief Financial Officer to leave Recipharm

Recipharm AB announces today that Henrik Stenqvist has resigned from his position with the company to pursue other opportunities.

Thomas Eldered, CEO of Recipharm, said: "During his time with Recipharm, Henrik has, amongst other things, further developed the Group’s financing as well as finance function, in terms of both its organization and competence. We are highly grateful for his contribution and wish him all the best for the future”.

Henrik Stenqvist will serve as CFO until later in the spring. A search process has commenced to appoint a new CFO.

Contact information
Thomas Eldered, CEO, telephone: +46 8 602 52 10

This information is information that Recipharm AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was submitted for publication on 26 February 2018, at 08:05 am CET.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit